Mizuho upgraded Solventum (SOLV) to Outperform from Neutral with a price target of $100, up from $85. Mizuho’s annual dental industry survey is more positive than prior years, the analyst tells investors in a research note. The firm cites a strong dental consumable and patient volume outlook and higher estimates for Solventum’s Acera acquisition for the upgrade.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SOLV: